Review highlights biomarkers that may improve outcomes in metastatic castration-resistant prostate cancer, suggesting their role in treatment decisions.
Although the recently approved prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) [ 177 Lu]Lu-PSMA-617 has improved outcomes for patients with metastatic castration-resistant prostate cancer (mCRPC), not all patients respond optimally to this treatment; even measuring response accurately can be difficult. Moreover, there is currently a lack of validated prognostic and predictive biomarkers for [ 177 Lu]Lu-PSMA-617 treatment in this patient population. There is, therefore, a growing need to identify biomarkers to help optimize patient selection for [ 177 Lu]Lu-PSMA-617 and guide therapy decision-making. This review explores the landscape of emerging clinical, molecular, and imaging biomarkers, and their potential utility as prognostic and/or predictive biomarkers in the context of [ 177 Lu]Lu-PSMA-617 treatment for patients with mCRPC.
No takes yet. Share an insight, caveat, or question.
Beltran et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: